These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27391638)

  • 41. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
    Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The hairless guinea-pig as a model for treatment of cumulative irritation in humans.
    Andersen F; Hedegaard K; Petersen TK; Bindslev-Jensen C; Fullerton A; Andersen KE
    Skin Res Technol; 2006 Feb; 12(1):60-7. PubMed ID: 16420540
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis.
    Stein L
    J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S39-49. PubMed ID: 15968263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topical antioxidants protect the skin from chemical-induced irritation in the repetitive washing test: a placebo-controlled, double-blind study.
    Schempp CM; Meinke MC; Lademann J; Ferrari Y; Brecht T; Gehring W
    Contact Dermatitis; 2012 Oct; 67(4):234-7. PubMed ID: 22624993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protective creams fail to prevent solvent-induced cumulative skin irritation - results of a randomized double-blind study.
    Schliemann S; Kleesz P; Elsner P
    Contact Dermatitis; 2013 Dec; 69(6):363-71. PubMed ID: 23844768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Skin barrier integrity and natural moisturising factor levels after cumulative dermal exposure to alkaline agents in atopic dermatitis.
    Angelova-Fischer I; Dapic I; Hoek AK; Jakasa I; Fischer TW; Zillikens D; Kezic S
    Acta Derm Venereol; 2014 Nov; 94(6):640-4. PubMed ID: 24531413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
    Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
    J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adjunctive use of a facial moisturizer SPF 30 containing ceramide precursor improves tolerability of topical tretinoin 0.05%: a randomized, investigator-blinded, split-face study.
    Schorr ES; Sidou F; Kerrouche N
    J Drugs Dermatol; 2012 Sep; 11(9):1104-7. PubMed ID: 23135655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of topical corticosteroid and tacrolimus on ceramides and irritancy to sodium lauryl sulphate in healthy skin.
    Jungersted JM; Høgh JK; Hellegren LI; Jemec GB; Agner T
    Acta Derm Venereol; 2011 May; 91(3):290-4. PubMed ID: 21365172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
    Housman TS; Keil KA; Mellen BG; McCarty MA; Fleischer AB; Feldman SR
    J Am Acad Dermatol; 2003 Jul; 49(1):79-82. PubMed ID: 12833013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Triamcinolone spray: no-rub application as effective as rub application.
    Draelos ZD
    J Cosmet Dermatol; 2015 Dec; 14(4):286-90. PubMed ID: 26133561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Randomized, Double-Blind, Placebo-Controlled Study of the Vasoconstrictor Potency of Topical 0.25% Desoximetasone Spray: A High to Super High Range of Potency (Class I to Class II) Corticosteroid Formulation.
    Oussedik E; Saleem MD; Feldman SR
    J Drugs Dermatol; 2017 Oct; 16(10):972-975. PubMed ID: 29036250
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of a botanical cleansing lotion on skin sebum and erythema of the face: A randomized controlled blinded half-side comparison.
    Weber N; Schwabe K; Schempp CM; Wölfle U
    J Cosmet Dermatol; 2019 Jun; 18(3):821-826. PubMed ID: 30022595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial.
    Feldman SR
    Cutis; 2007 Nov; 80(5 Suppl):20-8. PubMed ID: 18154220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy.
    Wilson DE; Kaidbey K; Boike SC; Jorkasky DK
    Clin Ther; 1998; 20(2):299-306. PubMed ID: 9589821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.
    Kempers S; Boguniewicz M; Carter E; Jarratt M; Pariser D; Stewart D; Stiller M; Tschen E; Chon K; Wisseh S; Abrams B
    J Am Acad Dermatol; 2004 Oct; 51(4):515-25. PubMed ID: 15389185
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized, observer-blind, split-face study to compare the irritation potential of 2 topical acne formulations over a 14-day treatment period.
    Ting W
    Cutis; 2012 Aug; 90(2):91-6. PubMed ID: 22988653
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peristomal dermatoses: a novel indication for topical steroid lotions.
    Lyon CC; Smith AJ; Griffiths CE; Beck MH
    J Am Acad Dermatol; 2000 Oct; 43(4):679-82. PubMed ID: 11004626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 4-Day evaluation of the irritation potential of topical desoximetasone 0.25% and 0.05% spray on light-exposed skin.
    Patel NU; Grammenos A; Gowda A; Onikoyi O; Feldman SR
    J Dermatolog Treat; 2018 Jun; 29(4):415-417. PubMed ID: 29098908
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Halobetasol propionate-loaded solid lipid nanoparticles (SLN) for skin targeting by topical delivery.
    Bikkad ML; Nathani AH; Mandlik SK; Shrotriya SN; Ranpise NS
    J Liposome Res; 2014 Jun; 24(2):113-23. PubMed ID: 24131382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.